Literature DB >> 28654416

The Evaluation of a Personal Narrative Language Intervention for School-Age Children With Down Syndrome.

Lizbeth Finestack1, Katy H O'Brien1, Jolene Hyppa-Martin1, Kristen A Lyrek1.   

Abstract

The purpose of this study was to evaluate the feasibility of an intervention focused on improving personal narrative skills of school-age children with Down syndrome (DS) using an approach involving visual supports. Four females with DS, ages 10 through 15 years, participated in this multiple baseline across participants single-subject experimental design study. Participants completed 18 intervention sessions that targeted personal narrative goals. Parents completed a survey regarding their perspectives of the intervention. Two participants made small treatment gains in mean length of utterance. One participant had small to medium gains on all macrostructural measures. Parent perspectives were positive. Results support the feasibility of personal narrative interventions for individuals with DS when visual support is provided.

Entities:  

Keywords:  Down syndrome; grammar; intervention; language; narrative

Mesh:

Year:  2017        PMID: 28654416     DOI: 10.1352/1944-7558-122.4.310

Source DB:  PubMed          Journal:  Am J Intellect Dev Disabil        ISSN: 1944-7558


  3 in total

Review 1.  Distributional Cues to Language Learning in Children With Intellectual Disabilities.

Authors:  Sara T Kover
Journal:  Lang Speech Hear Serv Sch       Date:  2018-08-14       Impact factor: 2.983

2.  Language Intervention in Down Syndrome: A Systematic Literature Review.

Authors:  Esther Moraleda-Sepúlveda; Patricia López-Resa; Noelia Pulido-García; Soraya Delgado-Matute; Natalia Simón-Medina
Journal:  Int J Environ Res Public Health       Date:  2022-05-16       Impact factor: 4.614

3.  Cross-Sectional Trajectories of Mental State Language Development in Children With Down Syndrome.

Authors:  Marie Moore Channell
Journal:  Am J Speech Lang Pathol       Date:  2020-04-14       Impact factor: 2.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.